Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients

Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients

Vascular calcification is a frequent complication in dialysis patients and is strongly associated with mortality. Its pathogenesis is complex and involves a series of markers that act on the vascular microenvironment. There is evidence that aldosterone is one of the biomarkers and may have a role in osteoinductive pathways.The aim of this study was to evaluate the effect of spironolactone, an inhibitor of mineralocorticoid receptor, in the progression of coronary calcification in patients undergoing peritoneal dialysis.

Inclusion Criteria:

• Coronary calcium score > 30 Agatston unit
• Peritoneal dialysis for at least 6 months

Exclusion Criteria:

• Use of spironolactone in the last 3 months
• Mean serum potassium > 6 mEq/L in the last 3 months
• Cardiac revascularization surgeries
• Arrhythmias
• Pregnancy